ArticleBMC medical genomics2026
Seminal long non-coding RNAs as prognostic non-invasive biomarkers in non-obstructive azoospermia.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Non-Coding RNA Biomarkers in Male Infertility: From Discovery to Clinical Actionability-A Narrative Review.Genes · 2026Review
- Seminal-Plasma Molecular Biomarkers as a Liquid Biopsy of Testicular Function: Toward AI-Ready Sperm-Retrieval Prediction in Non-Obstructive Azoospermia.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-obstructive azoospermia (NOA) is a multifactorial disease with high genetic and phenotypic heterogeneity. The main NOA pathogenesis is still unknown, which makes it challenging to find precise biomarkers for this condition. Long non-coding RNAs (lncRNAs) have been linked to many processes related to male reproductive health, such as spermatogenesis and sperm maturation. So, this study investigated a panel of seven lncRNAs from the seminal plasma of patients with NOA, which has the potential to be used as noninvasive prognostic biomarkers in NOA.
methodsThe differential gene expression for seven seminal lncRNAs was assessed for 106 male subjects—53 patients with NOA and 53 normal male volunteers using qRT-PCR —followed by correlational and bioinformatics analysis for the study results.
resultsSix lncRNAs - CDKN2B-AS1, H19, Linc-ROR, MALAT1, MIAT, and TUG1 - showed significant differential expression between NOA and normal males. Regarding the potency of this panel as NOA diagnostic biomarkers, TUG1 (0.94), CDKN2B-AS1 (0.90), H19 (0.90), Linc-ROR (0.87), and MALAT1 (0.80) showed to be excellent biomarkers. On the other side, the potency of this panel as prognostic biomarkers for TESE outcome prediction showed that Linc-ROR, TUG1, CDKN2B-AS1, and H19 were very good biomarkers.
conclusionLncRNAs hold the potential to improve the current knowledge about male infertility pathogenesis by highlighting their role in the pathophysiology of NOA and their potential clinical utility in its diagnosis and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.